How to evaluate the risk/benefit of trimodality therapy in locally advanced non-small-cell lung cancer.
The trimodality approach represented by concurrent chemoradiotherapy followed by surgical resection is a highly effective, but potentially toxic therapy for locally advanced non-small-cell lung cancer (NSCLC). In this review, we discuss the current status of this therapy in patients with mediastinal node-positive (N2) stage III NSCLC or superior sulcus tumor, and present an overview of the principles for optimisation of the risk/benefit. Numerous clinical questions remain, and enrolment of patients into well-designed clinical trials should be encouraged.
Kunitoh
H
H
Department of Internal Medicine and Thoracic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan. hkkunito@ncc.go.jp
Suzuki
K
K
D000465:Algorithms; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000145:classification / Q000473:pathology / Q000628:therapy*; D003131:Combined Modality Therapy / Q000009:adverse effects; D018450:Disease Progression; D005069:Evaluation Studies as Topic; D006801:Humans; D008175:Lung Neoplasms / Q000145:classification / Q000473:pathology / Q000628:therapy*; D013510:Pulmonary Surgical Procedures / Q000009:adverse effects; D018714:Radiotherapy, Adjuvant / Q000009:adverse effects; D018570:Risk Assessment